TrialInvestigational new drugs2019

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.

Jeffrey P Sharman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.